Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis
Open accessThe DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Osteoarthritis (OA) is a common disabling disease worldwide, with no effective and safe disease-modifying drugs (DMOAD) in the market. However, studies suggest that drugs, such as liraglutide, which possess strong potential in decreasing low-grade systemic inflammation may be effective in treating OA. Therefore, the aim of this study was to examine the anti-inflammatory, analgesic, and anti-degradative effects in OA using in vitro and in vivo experiments. The results showed that intra-articular injection of liraglutide alleviated pain-related behavior in in vivo sodium monoiodoacetate OA mouse model, which was probably driven by the GLP-1R-mediated anti-inflammatory activity of liraglutide. Moreover, liraglutide treatment significantly decreased IL-6, PGE 2 and nitric oxide secretion, and the expression of inflammatory genes in vitro in chondrocytes and macrophages in a dose-dependent manner. Additionally, liraglutide shifted polarized macrophage phenotype in vitro from the pro-inflammatory M1 phenotype to the M2 anti-inflammatory phenotype. Furthermore, liraglutide exerted anti-catabolic activity by significantly decreasing the activities of metalloproteinases and aggrecanases, a family of catabolic enzymes involved in cartilage breakdown in vitro. Overall, the findings of this study showed that liraglutide ameliorated OA-associated pain, possess anti-inflammatory and analgesic properties, and could constitute a novel therapeutic candidate for OA treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In another study, treatment of primary mouse chondrocytes with liraglutide reduced the mRNA expression levels of iNOS, MMP-13, and ADAMTS5, leading to a decrease in the secretion of inflammatory markers, including NO, prostaglandin E, and IL-6.348”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [348]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a sodium monoiodoacetate–induced model of osteoarthritis, a single intra-articular injection of 20 μg liraglutide reduced pain sensitivity and synovitis, in the absence of any changes in body weight (86).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [86]
In the citing paper
“In animal models, intra-articular administration of liraglutide reduced the secretion of inflammatory cytokines such as IL-6, the expression of inflammatory genes in chondrocytes, the amount of proinflammatory M1 macrophages, and improved pain-related behaviors104.”
From Incretin-based therapies for the treatment of obesity-related diseases (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Osteoarthritis: A disease of the joint as an organ
Loeser, R. F., Goldring, S. R., Scanzello, C. R., & Goldring, M. B. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34453 · Cited by 3,076
Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!)
Berenbaum, F. (2013) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.11.012 · Cited by 1,718
Self-citationGlasson, S. S., Blanchet, T. J., & Morris, E. A. (2007) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2007.03.006 · Cited by 1,514
The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis
Sellam, J., & Berenbaum, F. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.159 · Cited by 1,500
Self-citationLow-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
Robinson, W. H., Lepus, C. M., Wang, Q., Raghu, H., Mao, R., Lindstrom, T. M., & Sokolove, J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.136 · Cited by 1,438
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057
Bedson, J., & Croft, P. R. (2008) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-9-116 · Cited by 951
Synovitis score: discrimination between chronic low‐grade and high‐grade synovitis
Krenn, V, Morawietz, L., Burmester, G., Kinne, R. W., Mueller‐Ladner, U., Muller, B., & Haupl, T. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02508.x · Cited by 834
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
The role of obesity and adipose tissue dysfunction in osteoarthritis pain
Binvignat, M., Sellam, J., Berenbaum, F., & Felson, D. T. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01143-3 · Cited by 176
Self-citationRivera-Jiménez, J., Berraquero‐García, C., Pérez‐Gálvez, R., García‐Moreno, P. J., Espejo-Carpio, F. J., Guadix, A., & Guadix, E. M. (2022) · Food & Function · doi:10.1039/d2fo02223k · Cited by 172
Metadata
- Authors
- Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F.
- Affiliations
- Inserm (FR)
- Corresponding author
- Berenbaum, F.
- Venue
- Scientific Reports
- Published
- 2022-01-28
- Volume
- 12
- Issue
- 1
- Pages
- 1567-1567
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8799666
- OpenAlex
- W4210711301
- Cited by
- 160
- References
- 67
- Citations by year
- 2026: 50 · 2025: 70 · 2024: 25 · 2023: 9 · 2022: 6
- FWCI
- 20.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- liraglutide, osteoarthritis, GLP-1 receptor agonists, analgesia, anti-inflammatory activity, cartilage degeneration, chondrocytes, macrophage polarization, M1/M2 macrophages, interleukin-6, prostaglandin E2, nitric oxide, metalloproteinases, aggrecanase, intra-articular injection, disease-modifying osteoarthritis drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, RAW 264.7 Cells, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Analgesics, Animals, Anti-Inflammatory Agents, Disease Models, Animal, Macrophages, Male, Mice, Inbred C57BL, Nitric Oxide, Osteoarthritis, Chondrocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. https://app.cochat.ai/papers/10.1038/s41598-022-05323-7
- The paper
- Meurot, C., Martin, C., Sudre, L., Breton, J., Bougault, C., Rattenbach, R., Bismuth, K., Jacques, C., & Berenbaum, F. (2022). Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Scientific Reports. https://doi.org/10.1038/s41598-022-05323-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.